Yugo Kai

507 total citations
47 papers, 297 citations indexed

About

Yugo Kai is a scholar working on Oncology, Epidemiology and Surgery. According to data from OpenAlex, Yugo Kai has authored 47 papers receiving a total of 297 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 17 papers in Epidemiology and 13 papers in Surgery. Recurrent topics in Yugo Kai's work include Pancreatic and Hepatic Oncology Research (23 papers), Hepatitis C virus research (9 papers) and Hepatitis B Virus Studies (8 papers). Yugo Kai is often cited by papers focused on Pancreatic and Hepatic Oncology Research (23 papers), Hepatitis C virus research (9 papers) and Hepatitis B Virus Studies (8 papers). Yugo Kai collaborates with scholars based in Japan, Russia and United States. Yugo Kai's co-authors include Tasuku Nakabori, Kazuyoshi Ohkawa, Kenji Ikezawa, Tomohide Tatsumi, Ryoji Takada, Ryotaro Sakamori, Tetsuo Takehara, Hayato Hikita, Takuo Yamai and Satoshi Tanaka and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Hepatology.

In The Last Decade

Yugo Kai

37 papers receiving 295 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yugo Kai Japan	11	126	112	81	64	55	47	297
Takahiro Tomino Japan	10	87 0.7×	46 0.4×	88 1.1×	51 0.8×	57 1.0×	42	284
Şahin Laçin Türkiye	10	98 0.8×	53 0.5×	50 0.6×	69 1.1×	37 0.7×	37	242
Jiao Sang China	10	180 1.4×	109 1.0×	85 1.0×	86 1.3×	53 1.0×	16	386
Ayşegül Özakyol Türkiye	9	48 0.4×	114 1.0×	121 1.5×	82 1.3×	54 1.0×	25	327
Meng‐Shu Hsieh Taiwan	10	135 1.1×	130 1.2×	78 1.0×	95 1.5×	64 1.2×	12	364
Zuan Lin China	9	216 1.7×	103 0.9×	107 1.3×	26 0.4×	27 0.5×	18	325
Akinari Morinaga Japan	10	108 0.9×	43 0.4×	79 1.0×	87 1.4×	123 2.2×	25	312
Marjan Rahsaz Iran	12	77 0.6×	126 1.1×	71 0.9×	62 1.0×	23 0.4×	29	350
Heewon Kwak South Korea	9	76 0.6×	57 0.5×	56 0.7×	43 0.7×	33 0.6×	12	275
Mari Mandai Japan	8	55 0.4×	111 1.0×	136 1.7×	30 0.5×	54 1.0×	13	294

Countries citing papers authored by Yugo Kai

Since Specialization

Citations

This map shows the geographic impact of Yugo Kai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yugo Kai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yugo Kai more than expected).

Fields of papers citing papers by Yugo Kai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yugo Kai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yugo Kai. The network helps show where Yugo Kai may publish in the future.

Co-authorship network of co-authors of Yugo Kai

This figure shows the co-authorship network connecting the top 25 collaborators of Yugo Kai. A scholar is included among the top collaborators of Yugo Kai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yugo Kai. Yugo Kai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nakabori, Tasuku, Kaori Mukai, Noboru Maeda, et al.. (2025). Efficacy of Locoregional Treatment for Oligo-Drug-Resistant Lesions during First-Line Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma: A Single-Center Retrospective Study. Oncology. 104(3). 227–239.

Nakabori, Tasuku, Yugo Kai, Ryoji Takada, et al.. (2024). Abscopal effect in a patient with advanced hepatocellular carcinoma upon resuming bevacizumab in combination with atezolizumab after radiotherapy. Clinical Journal of Gastroenterology. 17(6). 1053–1057. 4 indexed citations

Yamai, Takuo, Kenji Ikezawa, Y. Kawamoto, et al.. (2024). Oil blotting paper for formalin fixation increases endoscopic ultrasound‐guided tissue acquisition‐collected sample volumes on glass slides. Cancer Medicine. 13(9). e7189–e7189. 1 indexed citations

Ikezawa, Kenji, Yugo Kai, Ryoji Takada, et al.. (2024). Zinc supplementation for dysgeusia in patients with unresectable pancreatic cancer. International Journal of Clinical Oncology. 29(8). 1173–1181. 2 indexed citations

Ohkawa, Kazuyoshi, Tasuku Nakabori, Kaori Mukai, et al.. (2024). Clinical validation of the suppressive impact of letrozole on liver fibrosis in patients with breast cancer undergoing continuous letrozole administration: A retrospective study. PLoS ONE. 19(10). e0311930–e0311930.

Kawamoto, Y., Takuo Yamai, Kenji Ikezawa, et al.. (2024). Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy for patients with pancreatic cancer. BMC Cancer. 24(1). 1000–1000. 2 indexed citations

Ikezawa, Kenji, Yugo Kai, Ryoji Takada, et al.. (2024). Long-term survival after systemic chemotherapy, chemoradiotherapy, and maintenance therapy for an older adult patient with recurrent pancreatic acinar cell carcinoma. Clinical Journal of Gastroenterology. 17(4). 771–775.

Yamai, Takuo, Kenji Ikezawa, Naotoshi Sugimoto, et al.. (2023). Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice. Cancers. 15(3). 970–970. 13 indexed citations

Ikezawa, Kenji, Yugo Kai, Ryoji Takada, et al.. (2023). Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features and treatment. Japanese Journal of Clinical Oncology. 54(3). 271–281. 11 indexed citations

10.

Ikezawa, Kenji, Toshitaka Morishima, Y. Kawamoto, et al.. (2023). An age-group analysis on the efficacy of chemotherapy in older adult patients with metastatic biliary tract cancer: a Japanese cancer registry cohort study. BMC Gastroenterology. 23(1). 263–263.

11.

Nakabori, Tasuku, Y. Kawamoto, Shingo Maeda, et al.. (2022). Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection. JGH Open. 6(5). 309–316. 7 indexed citations

12.

Yamai, Takuo, Kenji Ikezawa, Y. Kawamoto, et al.. (2022). Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel. PLoS ONE. 17(3). e0264653–e0264653. 9 indexed citations

13.

Ikezawa, Kenji, Toshitaka Morishima, Yugo Kai, et al.. (2022). Chemotherapy effectiveness and age-group analysis of older adult patients with metastatic pancreatic cancer: A Japanese cancer registry cohort study. Journal of Geriatric Oncology. 13(8). 1208–1215. 6 indexed citations

14.

Bessho, Hiroki, Y. Kawamoto, Shuhei Yamamoto, et al.. (2021). Water-slider method reduced colonic polyp fragmentation compared with conventional suction retrieval: A prospective randomized controlled study. Digestive and Liver Disease. 53(6). 717–721. 1 indexed citations

15.

Murai, Kazuhiro, Hayato Hikita, Yugo Kai, et al.. (2020). Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathway. Scientific Reports. 10(1). 941–941. 17 indexed citations

16.

Morishita, Naoki, Ryotaro Sakamori, Tomomi Yamada, et al.. (2020). Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection. PLoS ONE. 15(6). e0234811–e0234811.

17.

Kai, Yugo, et al.. (2019). Barium granuloma of the transverse colon. Gastrointestinal Endoscopy. 90(6). 993–994. 1 indexed citations

18.

Doi, Akira, Hayato Hikita, Yugo Kai, et al.. (2019). Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice. Journal of Gastroenterology. 54(5). 449–458. 6 indexed citations

19.

Nakabori, Tasuku, Hayato Hikita, Kazuhiro Murai, et al.. (2016). Sodium taurocholate cotransporting polypeptide inhibition efficiently blocks hepatitis B virus spread in mice with a humanized liver. Scientific Reports. 6(1). 27782–27782. 19 indexed citations

20.

Kato, Minoru, Masafumi Naito, Mina Kato, et al.. (2013). A case of HCC occurred 5 years and 17 years after sustained virological response of interferon therapy for chronic hepatitis C. Kanzo. 54(7). 491–498. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact